Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2018-07-03 globenewswire
SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on June 27, 2018, the Compensation Committee of the Board of Directors approved, effective as of June 29, 2018, the grant of an inducement stock option to purchase 87,500 shares of common stock and an award in the form of 25,000 restricted stock units to Glenn Brame, the Company’s newly appointed Senior Vice President, Technical Operations.
PTLA

53
OceanFirst Financial started at outperform with $33 stock price target at Raymond James

2018-06-28 marketwatch
Companies in the Financial sector have received a lot of coverage today as analysts weigh ...[...]
WR PTLA AEO EQGP TSLX SRPT OCFC

184
5 Biotech Stocks That Could Be the Next Amgen | InvestorPlace

2018-06-27 investorplace
Every investor buying clinical-stage biotech stocks dreams of one becoming the next Amgen (NASDAQ:AMGN). That is a drug developer that can turn a formula into a blockbuster drug capable of providing plenty of high cash flows and earnings for its shareholders. AMGN sold more than $22.8 billion worth of drugs last year alone.
ENTA DOVA AMGN GILD PTLA FLXN CELG NBIX

11
Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical Operations

2018-06-25 globenewswire
SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Glenn Brame as senior vice president of technical operations, effective immediately. Mr. Brame will report to Mardi Dier, interim co-president and chief financial officer, and will be responsible for leading the Company’s technical operations including process development, manufacturing, supply chain, quality assurance, and end-to-end process and platform optimization for Portola’s entire portfolio.
PTLA

11
The Market Needs A Glum Index - Cramer's Mad Money (6/18/18)

2018-06-19 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, June 18.
ZUO PTLA CBLK DOCU ZS PVTL COUP

290
BioSpace Movers and Shakers for Week of June 4th

2018-06-12 biospace
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors. The companies filled the roles with the talent they believe will drive the next stage of growth.
AUP EVFM PTLA AUPH DARE SRPT TRIL

17
PTLA / Portola Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-06-11 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PTLA

177
EVFM / Evofem Biosciences, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-11 fintel.io
Evofem Biosciences, Inc. (NASDAQ:EVFM) has 11 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 14,524,670 shares. Largest shareholders include Woodford Investment Management LLP, Invesco Ltd., Millennium Management Llc, Panagora Asset Management Inc, Bank Of America Corp /de/, BlackRock Inc.
EVFM BAC RY PTLA RY.PRSCL GALPW RBCDF STML BAC BLK RY UBS VBLT UBS.PRDCL RY.PRS GALE VBLTF RY.PRT ULSGF GALEW IVZ

28
PTLA / Portola Pharmaceuticals, Inc. FORM S-8

2018-06-08 sec.gov
Form S-8 As filed with the Securities and Exchange Commission on June 8, 2018 Registration No. 333-
PTLA

633
Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

2018-06-07 seekingalpha
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested.
SGEN NKTR DCPH ATRS NVCR PTLA LOXO CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE BMY MOR EXEL BLUE XNCR INCY NBIX GLPG ABEO AKCA HCM HCM ADMS GSK JNCE MRK IONS NVS ABEOW ARRY

12
PTLA / Portola Pharmaceuticals, Inc. DEFA14A

2018-06-06 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
PTLA

11
Portola Pharmaceuticals’ CEO to Step Down

2018-06-05 biospace
Portola Pharmaceuticals chief executive officer, William Lis, plans to retire as both chief executive and board member. He will officially leave the company on August 1, 2018. Afterward, he will stay in an advisory role.
PTLA

14
After-hours buzz: SBUX, TWTR & more

2018-06-04 cnbc
Shares of Starbucks dropped 1.4 percent in extended trading, after Executive Chairman Howard Schultz announced he would be stepping down effective June 26. Schultz has played an essential role in the success of the coffee company, serving as CEO from 1987 through 2000 and again from 2008 through 2017, when he resigned from the position to be replaced by Kevin Johnson. Schultz's decision comes about a week after Starbucks closed for an afternoon for company-wide sensitivity training following the arrest of two black men in a Philadelphia Starbucks.
PTLA TRI ANW COUP

22
PTLA / Portola Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-06-04 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PTLA

13
Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018

2018-06-04 globenewswire
SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that William Lis has informed the Board of Directors of his plans to retire as Chief Executive Officer and member of the board. Mr. Lis will continue to serve as CEO and member of the board through August 1, 2018 to ensure a smooth transition, after which time he will remain in an advisory role.
PTLA

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

CUSIP: 737010108